

Haematologica
HAEMATOL/2015/133421
Version 3

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell
non-Hodgkin lymphoma

Disclosures: Competing interests: All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that this work was supported by F. Hoffmann-La Roche Ltd; G.C received honoraria and consultancy fees from F. Hoffmann-La Roche Ltd outside the submitted work; F.M received honoraria for scientific speeches (not Speakers Bureau) from Mundipharma, Gilead Sciences and Spectrum Pharmaceuticals, honoraria for advisory boards from Mundipharma, Gilead Sciences, Spectrum Pharmaceuticals and Bayer, and a travel grant from Genentech Inc. outside the submitted work; G.S received grants and personal fees from F. Hoffmann-La Roche Ltd and Genentech Inc. outside the submitted work; F.H-P, M.W, A.T-H and D.C were employed by F-Hoffmann-La Roche Ltd during the study and outside the submitted work.

Contributions: Collected data: G.C, F.H-P, F.M, G.S Analyzed data: G.C, F.H-P, F.M, D.J.C, M.W, G.S Interpreted the data: G.C, F.H-P, D.J.C, M.W, A.T-H, F.M, G.S Wrote the manuscript: G.C, D.J.C, M.W, A.T-H, F.M, G.S Approved the final version: G.C, F.H-P, F.M, G.S, M.W, A.T-H, D.J.C